ADMA Biologics Upgraded to 'Buy' Rating

Wall Street Zen analysts raise ADMA Biologics stock recommendation from 'hold' to 'buy'

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

ADMA Biologics (NASDAQ:ADMA), a biopharmaceutical company focused on plasma-derived biologics, has been upgraded by analysts at Wall Street Zen from a 'hold' rating to a 'buy' rating in a new research report. The report cited ADMA's strong financial performance and growth potential in the specialty plasma market.

Why it matters

This upgrade from Wall Street Zen is a positive sign for ADMA Biologics, as it indicates increased confidence in the company's ability to execute on its business strategy and capitalize on opportunities in the plasma-derived biologics market. The 'buy' rating could lead to increased investor interest and potentially drive up the stock price.

The details

According to the research report, Wall Street Zen analysts cited ADMA Biologics' recent financial results, which showed strong revenue growth and profitability. The company's marketed product portfolio, including its IGIV therapy BIVIGAM, was also noted as a key factor in the upgrade. Additionally, the analysts believe ADMA is well-positioned to address unmet needs in immune-compromised and high-risk patient populations.

  • ADMA Biologics reported its latest earnings on February 25, 2026.
  • The Wall Street Zen research report was issued on March 2, 2026.

The players

ADMA Biologics

A biopharmaceutical company headquartered in Ramsey, New Jersey that focuses on the development, manufacturing, and commercialization of specialty plasma-derived biologics.

Wall Street Zen

An equity research firm that provides investment analysis and recommendations to clients.

Weiss Ratings

A financial research and ratings agency that provides independent ratings and analysis on stocks, mutual funds, and other financial products.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.